Use of biomarkers to select the target population for clinical trials in subjects with mild cognitive impairment

Use of Biomarkers to Select the Target Population for Clinical Trials

References

  1. 1.
    Visser, PJ and FR Verhey, Mild cognitive impairment as predictor for Alzheimer’s disease in clinical practice: effect of age and diagnostic criteria. Psychol Med 2008; 38: 113–122.PubMedCrossRefGoogle Scholar
  2. 2.
    Jelic, V, M Kivipelto, and B Winblad, Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psychiatry 2006; 77: 429–438.PubMedCrossRefGoogle Scholar
  3. 3.
    Visser, PJ, P Scheltens, and FR Verhey, Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer’s disease? J Neurol Neurosurg Psychiatry 2005; 76: 1348–1354.PubMedCrossRefGoogle Scholar
  4. 4.
    Salloway, S, et al., Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 2004; 63: 651–657.PubMedGoogle Scholar
  5. 5.
    Visser, PJ, et al., Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology 2006; 67: 1201–1207.PubMedCrossRefGoogle Scholar
  6. 6.
    Fox, NC, et al., Imaging of onset and progression of Alzheimer’s disease with voxel-compression mapping of serial magnetic resonance images. Lancet 2001; 358: 201–205.PubMedCrossRefGoogle Scholar
  7. 7.
    O’Brien, JT, et al., Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology 2001; 56: 1386–1388.PubMedGoogle Scholar
  8. 8.
    Jack, CR, Jr., et al., Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology 2008; 70: 1740–1752.PubMedCrossRefGoogle Scholar
  9. 9.
    Visser, PJ, Diagnosis of predementia AD in a clinical setting, in Alzheimer’s disease. A physician’s guide to practical management. B. Zoeller-Richter, Editor. 2003, Humana Press: New Yersey. p. 157–164.Google Scholar
  10. 10.
    Nordberg, A, PET imaging of amyloid in Alzheimer’s disease. Lancet Neurol 2004; 3: 519–527.PubMedCrossRefGoogle Scholar
  11. 11.
    Blennow, K and H Hampel, CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2003; 2: 605–613.PubMedCrossRefGoogle Scholar
  12. 12.
    Koivunen, J, et al., PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 2008; 26: 378–83.PubMedCrossRefGoogle Scholar
  13. 13.
    Forsberg, A, et al., PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29: 1456–1465.PubMedCrossRefGoogle Scholar
  14. 14.
    Alexander, GE, et al., Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer’s Disease Treatment Studies. Am J Psychiatry 2002; 159: 738–745.PubMedCrossRefGoogle Scholar
  15. 15.
    Zetterberg, H, et al., Intra-individual stability of CSF biomarkers for Alzheimer’s disease over two years. J Alzheimers Dis 2007; 12: 255–260.PubMedGoogle Scholar
  16. 16.
    Brys, M, et al., Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging 2007.Google Scholar
  17. 17.
    Andersson, C, et al., Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiol Aging 2008; 29: 1466–1473.PubMedCrossRefGoogle Scholar
  18. 18.
    Engler, H, et al., Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain 2006; 129: 2856–2866.PubMedCrossRefGoogle Scholar
  19. 19.
    Busse, A, et al., Mild cognitive impairment: long-term course of four clinical subtypes. Neurology 2006; 67: 2176–2185.PubMedCrossRefGoogle Scholar
  20. 20.
    Winblad, B, et al., Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008; 70: 2024–2035.PubMedCrossRefGoogle Scholar
  21. 21.
    Feldman, HH, et al., Effect of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007; 6: 501–512.PubMedCrossRefGoogle Scholar
  22. 22.
    Petersen, RC, et al., Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379–2388.PubMedCrossRefGoogle Scholar
  23. 23.
    Johnson, SA and VF Simmon, Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine CX516 in elderly participants with mild cognitive impairment: a progress report. J Mol Neurosci 2002; 19: 197–200.PubMedCrossRefGoogle Scholar
  24. 24.
    Thal, LJ, et al., A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment. Neuropsychopharmacology 2005.Google Scholar

Copyright information

© Serdi and Springer Verlag France 2009

Authors and Affiliations

  1. 1.Department of PsychiatryUniversity of MaastrichtMaastrichtThe Netherlands
  2. 2.Department of NeurologyVUMCAmsterdamThe Netherlands

Personalised recommendations